Asuntos regulatorios farmacéuticos: acceso abierto

Role of cannabidiol in neurological dysfunction disorders

Abstract

Allam Moore and Asada Witas

A growing body of preclinical evidence shows that certain cannabinoids, including cannabidiol (CBD) and its derivatives, may play a role in myelinating processes and are promising small particles to be created as a treatment option for the treatment of demyelinating diseases such as multiple sclerosis (MS), stroke, and traumatic brain injury (TBI), which are three of the most widespread demyelinating diseases. Due to the properties described for CBD and its fascinating profile in relation to humans, both the phytocannabinoid and its derivatives could be considered as potential candidates for clinical use. In this study, we will summarize the current advances in the use of CBD and other cannabinoids as potential future medicines. While new research is accelerating the interaction for the era of new drug competitors and drug target screening, the coordinated effort of key participants, for example, key researchers, physicians, and pharmaceutical companies, is expected to bring new treatments to patients.